65,437 trials
HIV Infections
Primary: Participants With Plasma HIV RNA < 200 Copies/mL 48 Weeks After Randomization — 219; 223 participants
Acute Myocardial Infarction
Primary: ECG-documented Ventricular Fibrillation or Symptomatic Sustained Ventricular Tachycardia (VT) — 25; 8; 3; 2 participants
Hemophilia A
Primary: The Area Under the Concentration Curve for Human-cl rhFVIII Compared to Kogenate FS — 0.39; 0.38 h IU/mL (IU/kg)
HIV
Primary: Mean Bone Mineral Density Changes From Baseline to 48 Weeks as Measured by DXA Scan — -5.2; -2.9 percentage change
Myopia
Primary: Monocular Visual Acuity Assessment — -0.05; -0.04 logMAR
Thyroid Cancer
Primary: Change in Tumor Size — 4.7 cm
COPD
Primary: FEV1, E0-4; the Average Value at Visit 5 From Before to 4 Hours After Morning Dose (Peak Effect) — 0.21; 0.17; 0.14; 0.16 Litre
Schizophrenia
Primary: Percentage of Participants Achieving Symptomatic Remission by Means of Positive and Negative Syndrome Scale (PANSS) — 11.74 percentage of participants
Chronic Pain
Primary: Long-term Sequelae — 10; 13 percentage of participants
Asthma · Rheumatic Disease
Primary: Rey Auditory Verbal Learning Test (RAVLT) — 44.8; 44.1 words
Idiopathic Growth Hormone Deficiency · Turner Syndrome
Primary: Change From Baseline in Height at Year 1 — 103.6; 103.5; 9.8; 8.6 centimeter
Type 2 Diabetes Mellitus
Primary: Percentage of Patients Who Achieved Glycemic Target of HbA1c ≤ 7.0% With Minimal Weight Gain (≤ 1 Kg) at Month 12. — 35.0; 15.8 percentage of patients
Breast Augmentation
Primary: To Evaluate if the Subject Has Macrolane Deposits in the Breast Seven Years Post Treatment, Using a Comprehensive MRI Investigation — 4 participants with remaining product
Neuroblastoma
Primary: Overall Response - Complete Response (CR), Very Good Partial Response (VGPR) and Partial Response (PR) — 5; 3 participants
Acne Vulgaris
Primary: Absolute Change From Baseline in Facial Inflammatory Lesion Count (Nodules, Papules, and Pustules). — -7.8; -15.6 lesion count — p=0.006